Johnston SRD, Hegg R, Im SA. et al
Phase III, randomized study of dual human epidermal growth factor receptor 2 (HER2) blockade with lapatinib plus trastuzumab in combination with an aromatase inhibitor in postmenopausal women with HER2-positive, hormone receptor-positive metastatic breast cancer: updated results of ALTERNATIVE.
J Clin Oncol 2021;
39 (01) 79-89
Download Bibliographical Data